Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy

Scientific paper - Original scientific paper

• Author: Jelena Dimnjaković
• Author: Tamara Buble
• Author: Pero Ivanko
• Author: Ivan Pristaš
• Author: Ognjen Brborović
• Author: Hana Brborović
• Author's institution: University of Zagreb; School of Medicine; (Department of Social Medicine and Health Care Organization)
• Author's institution: University of Zagreb; School of Medicine; (Department of Environmental and Occupational Health)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Public Health and Health Care; Health Ecology
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Public Health and Health Care; Social Medicine

Abstract (english)

There is a scarcity of information on the population with diabetes mellitus type 2 and cardiomyopathy (PDMC) in COVID-19, especially on the association between anti-diabetic medications and COVID-19 outcomes. Study is designed as a retrospective cohort analysis covering 2020 and 2021. Data from National Diabetes Registry (CroDiab) were linked to hospital data, primary healthcare data, the SARS-CoV-2 vaccination database, and the SARS-CoV-2 test results database. Study outcomes were cumulative incidence of SARS-CoV-2 positivity, COVID-19 hospitalizations, and COVID-19 deaths. For outcome predictors, logistic regression models were developed. Of 231 796 patients with diabetes mellitus type 2 in the database, 14 485 patients had cardiomyopathy. The two2-year cumulative incidence of all three studies' COVID-19 outcomes was higher in PDMC than in the general diabetes population (positivity 15.3% vs. 14.6%, p = 0.01; hospitalization 7.8% vs. 4.4%, p 

• Keywords (english): COVID-19 Vaccines / therapeutic use; COVID-19 / complications; Cardiomyopathies / chemically induced; Diabetes Mellitus, Type 2 / complications; Diabetes Mellitus, Type 2 / drug therapy; Diabetes Mellitus, Type 2 / epidemiology; Dipeptidyl-Peptidase IV Inhibitors / therapeutic use; Humans; Hypoglycemic Agents / therapeutic use; Insulin / therapeutic use; Retrospective Studies; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors / therapeutic use; Sulfonylurea Compounds / therapeutic use; Substances
• Language: english
• Publication type: Scientific paper - Original scientific paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Scientific Reports
• Numbering: vol. 14, no. 1, 7227
• e-ISSN: 2045-2322
• DOI: https://doi.org/10.1038/s41598-024-57871-9
• URN:NBN: urn:nbn:hr:105:920092
• Publication: 2024-03-27
• Document URL: https://www.nature.com/articles/s41598-024-57871-9
• Type of resource: Text
• Access conditions: Open access
• Created on: 2024-10-22 08:47:06